Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation, Biologic therapy.

University Hospital, Amiens, France.

Survival: monthsCountry:France
Toxiciy Grade:5City/State/Province:Amiens
Treatments:Chemotherapy, Radiation, Biologic therapyHospital:University Hospital
Drugs:Journal:Link
Date:Apr 2014

Description:

Patients:
This phase 2 study involved glioblastoma patients who were divided into two treatment groups. Group A consisted of 60 patients with a median age of 60.2 years, 56.7% of whom were male. Group B had 60 patients with a median age of 60.9 years, 61.7% of whom were male.

Treatment:
Patients in group A received radiation therapy, biologic therapy with bevacizumab, and chemotherapy with irinotecan and temozolomide.

Patients in group B received radiation therapy and temozolomide only.

Toxicities:
Treatment-related deaths due to intracranial bleeding and GI perforation were reported for group A. Blood clots, diarrhea, and inflammation of the stomach lining were also reported.

Treatment-related deaths due to intracranial bleeding and GI perforation were reported for group B. Blood clots were also reported.

Results:
The median overall survival rates for groups A and B were both 11.1 months.

Support:
This study was partially supported by the pharmaceutical companies Roche and Pfizer.

Correspondence: Dr. Bruno Chauffert; email: [email protected]



Back